A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya

American Journal of Tropical Medicine and Hygiene

Volumn 73, Issue 5, 2005, Pages 871-876

  Wasunna, Monique K ^b   Rashid, Juma R ^b   Mbui, Jane ^b   Kirigi, George ^b   Kinoti, Dedan ^b   Lodenyo, Hudson ^b   Felton, J Mark ^a   Sabin, Antony J ^a   Horton, John ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CREATININE; FUROSEMIDE; PREDNISONE; SITAMAQUINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DERMATITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; GLOMERULONEPHRITIS; HEADACHE; HEMATURIA; HUMAN; INFECTION; KENYA; KIDNEY DYSFUNCTION; LEISHMANIA DONOVANI; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; TREATMENT FAILURE; UREA NITROGEN BLOOD LEVEL; VISCERAL LEISHMANIASIS;

LEISHMANIA DONOVANI;

EID: 28044436746     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2005.73.871     Document Type: Article

References (21)

1. Zijlstra EE, el-Hassan AM, 2001. Leishmantasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med live; 95 (Suppl 1): S27-S58.
2. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hasan SM, Narain S, Roy RK, 1998. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? Ann Trop Med Parasitol 92: 561-569.
3. Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E, Davidson R, 1995. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 21: 188-193.
4. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD, 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 25-32.
5. Chunge CN, Owate J, Pamba HO, Donno L, 1990. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 84: 221-225.
6. World Heath Organization, September 2003. Miltefosine: what next? T D R New. Available from http://www.who.int/tdr/ publications/tdrnews/newsVO/ miltefosine.htm.
7. More B, Bhatt H, Kukreja V, Ainapure S, 2003. Miltefosine: great expectations against visceral leishmaniasis. J Postgrad Med 49: 101-103.
8. Prasad R, Kumar R, Jaiswal BP, Singh UK, 2004. Miltefosine: an oral drug for visceral leishmaniasis. Indian J Peiliatr 71: 143-144.
9. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, Sanchez J, Schuster B, Grogl M, 2001. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 65: 685-689.
10. Sherwood JA, Gachihi GS, Muigai RK, Skillman DR, Mugo M, Rashid JR, Wasunna KM, Were JB, Kasili SK, Mbugua JM, Kirigi G, Shaefer KU, Oster CN, Fleckenstein LL, Berman JD, Brewer TG, Roberts CR, Johnson AJ, Schuster BG, 1994. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 19: 1034-1039.
11. Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, Horton J, 2005. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 73: 871-876.
12. Chulay JD, Bryceson AD, 1983. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 32: 475-479.
13. National Cancer Institute, 2003. Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). Cancer Therapy Evaluation Program. Available from http://ctep.cancer.gov/ reporting/etc.html.
14. Yeates C, 2002. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr Opin Invest Drugs 3: 1446-1452.
15. Dutra M, Martinelli R, de Carvalho EM, Rodrigues LE, Brito E, Rocha H, 1985. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 6: 22-27.
16. Duarte MI, Silva MR, Goto H, Nicodemo E, Amato Neto V, 1983. Interstitial nephritis in human kala-azar. Trans R Soc Trop Med Hyg 77: 531-537.
17. Salgado Fillio N, Ferreira TM, Costa JM, 2003. Involvement of the renal function in patients with visceral leishmaniasis (kalaazar). Rev Soc Bras Med Trop 36: 217-221.
18. Caravaca F, Munoz A, Pizarro JL, Saez de Santamaria J, Fernandez-Alonso J, 1991. Acute renal failure in visceral leishmaniasis. Am J Nephrol 11: 350-352.
19. De Brito T, Hoshino-Shimizu S, Neto VA, Duarte IS, Penna DO, 1975. Glomerular involvement in human kala-azar. A light, immunofluorescent, and electron microscopic study based on kidney biopsies. Am J Trop Med Hyg 24: 9-18.
20. Central Bureau of Statistics Ministry of Planning and National Development, 2003. Kenyan Demographic and Health Survey. Available from http://www.cbs.go.ke/kdhs2003_highlights. html.
21. Rashid JR, Nyakundi PM, Kirigi G, Kinoti D, Wasunna MK, 2002. Compassionate use of sitamaquine in an HIV-positive patient with visceral leishmaniasis. Trans R Soc Trop Med Hyg 96: 533-534.